News from pharmaengine A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jul 25, 2016, 05:38 ET PharmaEngine Announces ONIVYDE(R) Regimen Receives CHMP Positive Opinion for the Treatment of Metastatic Pancreatic Cancer

PharmaEngine, Inc. (TWO: 4162) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...


May 31, 2016, 08:00 ET PharmaEngine Announces Initiation of Global Pivotal Trial of PEP503 (NBTXR3) in Soft Tissue Sarcoma in Asia Pacific Region

PharmaEngine Inc. (TWO: 4162) announced today that the first patient has been dosed in a global pivotal phase II/III trial of PEP503 (NBTXR3) in soft ...


May 10, 2016, 09:24 ET PharmaEngine Announces Korean Ministry of Food and Drug Safety Accepted the NDA Filing of ONIVYDE(R) for the Treatment of Metastatic Pancreatic Cancer

PharmaEngine, Inc. (TWO: 4162) announced that Korean Ministry of Food and Drug Safety (MFDS, previously called Korean Food and Drug Administration)...


Mar 05, 2016, 01:09 ET PharmaEngine Announces Taiwan FDA Granting the Product License of ONIVYDE™ (Irinotecan Liposome Injection) for the Treatment of Metastatic Pancreatic Cancer

PharmaEngine, Inc. (TWO: 4162) announced that TFDA (Taiwan Food and Drug Administration) approved the product license of ONIVYDE™ (irinotecan...


Nov 22, 2015, 10:36 ET PharmaEngine Announces the Lancet Publication of the ONIVYDE(TM) Phase 3 NAPOLI-1 Study

PharmaEngine, Inc. (TWO: 4162) announced that The Lancet has published the manuscript entitled "Nanoliposomal irinotecan with fluorouracil and...


Oct 23, 2015, 12:15 ET PharmaEngine Announces U.S. FDA Approves Merrimack's ONIVYDE(TM) (irinotecan liposome injection)

PharmaEngine, Inc. (TWO: 4162) announced the U.S. FDA has approved Merrimack's (NASDAQ: MACK) ONIVYDE TM (irinotecan liposome injection) in...


Oct 22, 2015, 09:05 ET PharmaEngine Announces Taiwan FDA Approval of ONIVYDE (TM) (irinotecan liposome injection) for the Treatment of Metastatic Pancreatic Cancer

PharmaEngine, Inc. (TWO: 4162) announced that the Taiwan Food and Drug Administration (TFDA) has approved ONIVYDETM (irinotecan liposome injection)...